Literature DB >> 22961090

Leflunomide: friend or foe for systemic lupus erythematosus?

Guo-Cui Wu1, Xiao-Di Xu, Qiong Huang, Hua Wu.   

Abstract

Leflunomide is a new immunosuppressive medicine that has been effectively used in the therapy of rheumatoid arthritis and subsequently used with success in animal models and patients with systemic lupus erythematosus (SLE). However, its use has also been associated with significant and serious adverse reactions involving hematological, hepatic, immune, dermatological and respiratory systems. In the current review, we attempt to describe the two sides of this drug in the treatment of SLE.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22961090     DOI： 10.1007/s00296-012-2508-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  35 in total

1.  Leflunomide induced vasculitis--a dose-response relationship.

Authors:  A T Y Chan; A Bradlow; J McNally
Journal:  Rheumatology (Oxford)       Date:  2003-03       Impact factor: 7.580

Review 2.  Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis.

Authors:  F Soliotis; M Glover; A S M Jawad
Journal:  Ann Rheum Dis       Date:  2002-09       Impact factor: 19.103

3.  Subacute cutaneous lupus erythematosus associated with leflunomide.

Authors:  O A Kerr; C S Murray; M J Tidman
Journal:  Clin Exp Dermatol       Date:  2004-05       Impact factor: 3.470

4.  Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis.

Authors:  S K Manna; A Mukhopadhyay; B B Aggarwal
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

5.  Vasculitis occurring during leflunomide therapy.

Authors:  E A Holm; E Balslev; G B Jemec
Journal:  Dermatology       Date:  2001       Impact factor: 5.366

6.  Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction.

Authors:  Yasuyuki Kamata; Hiroyuki Nara; Takeshi Kamimura; Kengo Haneda; Masahiro Iwamoto; Junichi Masuyama; Hitoaki Okazaki; Seiji Minota
Journal:  Intern Med       Date:  2004-12       Impact factor: 1.271

7.  Development of autoimmunity in MRL/lpr mice and the effects of drugs on this murine disease.

Authors:  R R Bartlett; S Popovic; R X Raiss
Journal:  Scand J Rheumatol Suppl       Date:  1988

8.  Leflunomide in subacute cutaneous lupus erythematosus - two sides of a coin.

Authors:  Anke Suess; Michael Sticherling
Journal:  Int J Dermatol       Date:  2008-01       Impact factor: 2.736

9.  Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

Authors:  J S Smolen; J R Kalden; D L Scott; B Rozman; T K Kvien; A Larsen; I Loew-Friedrich; C Oed; R Rosenburg
Journal:  Lancet       Date:  1999-01-23       Impact factor: 79.321

10.  Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity.

Authors:  Eric N van Roon; Tim L Th A Jansen; Nella M Houtman; Piet Spoelstra; Jacobus R B J Brouwers
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606
View more
  8 in total

Review 1.  Systemic lupus erythematosus: a therapeutic challenge for the XXI century.

Authors:  Manuel F Ugarte-Gil; Graciela S Alarcón
Journal:  Clin Rheumatol       Date:  2014-02-28       Impact factor: 2.980

2.  The beneficial effect of leflunomide on systemic lupus erythematosus: the role of Tregs repopulation?: Comment on: Leflunomide: friend or foe for systemic lupus erythematosus? Rheumatol Int 2013, 33(2):273-6.

Authors:  Jae Il Shin
Journal:  Rheumatol Int       Date:  2013-06-14       Impact factor: 2.631

3.  Effect of Leflunomide on the Abnormal Expression of Lipid Rafts and F-Actin in B Lymphocytes from Patients with Systemic Lupus Erythematosus.

Authors:  Guang Fu Dong; Xiao Zhang; De Ning He; Ling Li; Guang Feng Zhang
Journal:  J Immunol Res       Date:  2015-05-18       Impact factor: 4.818

4.  A Retrospective Study on the Safety and Efficacy of Leflunomide in Dogs.

Authors:  M Sato; J K Veir; M Legare; M R Lappin
Journal:  J Vet Intern Med       Date:  2017-08-21       Impact factor: 3.333

Review 5.  The key player in the pathogenesis of environmental influence of systemic lupus erythematosus: Aryl hydrocarbon receptor.

Authors:  Jingwen Wu; Tianyi Pang; Ziyuan Lin; Ming Zhao; Hui Jin
Journal:  Front Immunol       Date:  2022-08-30       Impact factor: 8.786

Review 6.  Current and emerging treatment options in the management of lupus.

Authors:  Natasha Jordan; David D'Cruz
Journal:  Immunotargets Ther       Date:  2016-03-02

Review 7.  The Efficacy and Safety of Leflunomide for the Treatment of Lupus Nephritis in Chinese Patients: Systematic Review and Meta-Analysis.

Authors:  Heng Cao; Yuefeng Rao; Lin Liu; Jin Lin; Hongyu Yang; Xingguo Zhang; Zhong Chen
Journal:  PLoS One       Date:  2015-12-15       Impact factor: 3.240

8.  The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study.

Authors:  Andreas Muehler; Hella Kohlhof; Manfred Groeppel; Daniel Vitt
Journal:  Drugs R D       Date:  2019-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.